VivoSeq
Other

Single Ascending Dose

0

Pipeline Programs↗

25

Active Trials↗

99

Companies Involved↗

Single Ascending Dose is an early-stage landscape with 0 programs across 99 companies. The most active players are AstraZeneca, Pfizer, Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

45/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalBiogen logo

Biogen

0 programs

PreclinicalAstellas logo

Astellas

0 programs

PreclinicalRoche logo

Roche

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

250

clinical trials

Completed198 · 79%
Recruiting15 · 6%
Terminated14 · 6%
Unknown status9 · 4%
Not yet recruiting8 · 3%
Withdrawn4 · 2%
Other2 · 1%

Clinical Trials

Trial Activity

250 trials

Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults
Recruiting·MMetro International Biotech, LLC·Phase 1·NCT06815991·32 enrolled
A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers
Recruiting·AAdipoPharma LLC·Phase 1·NCT07223333·56 enrolled
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Recruiting·AArcutis Biotherapeutics, Inc.·Phase 1·NCT07453602·125 enrolled
Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects
Recruiting·SSirnaomics·Phase 1·NCT05844293·40 enrolled
Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants
Recruiting·SSuzhou Ribo Life Science Co. Ltd.·Phase 1·NCT07042594·32 enrolled
A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults and Adults With FV Leiden or Prothrombin G20210A Mutation
Recruiting·CCity Therapeutics·Phase 1·NCT07430397·128 enrolled
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants
Recruiting·Medicines for Malaria Venture logoMedicines for Malaria Venture·Phase 1·NCT07011511·72 enrolled
Single Ascending Dose and Multiple Ascending Dose Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants
Recruiting·MMDI Therapeutics, Inc.·Phase 1·NCT07220889·52 enrolled
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
Recruiting·AAntidote Therapeutics, Inc·Phase 1·NCT07215923·15 enrolled
A Single Ascending Dose of HRS-2162 in Healthy Subjects
Recruiting·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 1·NCT07195604·64 enrolled
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Injection
Recruiting·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 1·NCT07241923·48 enrolled
Phase 1 Single Ascending Dose Study
Recruiting·NNeuramedy Co. Ltd.·Phase 1·NCT06934941·36 enrolled
A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085
Recruiting·CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logoCSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT07412353·74 enrolled
A Single Ascending Dose Study of HM17321 in Healthy Adult Participants
Recruiting·Hanmi Pharmaceutical Company Limited logoHanmi Pharmaceutical Company Limited·Phase 1·NCT07219589·40 enrolled
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
Recruiting·WWave Life Sciences Ltd.·Phase 1/2·NCT06405633·24 enrolled
Page 1 of 17

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)